ArticleActa dermato-venereologica2025
Dementia Risk in Psoriasis Patients Treated with Biologics: A Propensity Score-matched Population-based Cohort Study.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer's Disease?Dermatology and therapy · 2026Review
- From Skin to Brain: Key Genetic Mediators Associating Cutaneous Inflammation and Neurodegenerative Diseases.Genes · 2025Review
- Alzheimer's disease heterogeneity and co-pathologies: Defining novel targets, biomarkers, modalities, and research methodologies.Alzheimer's & dementia (New York, N. Y.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Translational research and animal models suggest that psoriasis treatments may have neuroprotective effects and reduce dementia risk. This study evaluates the association between biologic therapies for psoriasis and dementia incidence. A retrospective cohort included patients aged 65 or older with psoriasis, divided into 2 groups: those receiving biologic therapy following systemic treatment and those on systemic treatment alone. Patients with prior dementia were excluded. Dementia diagnosis was assessed at least 12 months after biologic initiation. Propensity score matching yielded 1,766 patients (883 per group). Biologic therapy was associated with a 53% reduced dementia risk (hazard ratio 0.47, 95% confidence interval 0.323-0.699), supported by a multivariate Cox model (adjusted hazard ratio 0.52, 95% confidence interval 0.392-0.699). These findings suggest that biologic therapies targeting tumour necrosis factor-alpha, interleukin-17, and interleukin-23 may reduce the risk of dementia, even after adjusting for age and other confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.